VivoSeq
Other

Bariatric Patients

0

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

Bariatric Patients is an early-stage landscape with 0 programs across 1 company. The most active players are Pacira Pharmaceuticals, Inc.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

75/100

Attrition Rate

22/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pacira Pharmaceuticals, Inc logo

Pacira Pharmaceuticals, Inc

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

9

clinical trials

Completed6 · 67%
Active, not recruiting1 · 11%
Withdrawn1 · 11%
Terminated1 · 11%

Clinical Trials

Trial Activity

9 trials

Testosterone in Bariatric Patients
Active, not recruiting·EEsbjerg Hospital - University Hospital of Southern Denmark·Phase 4·NCT03721497·64 enrolled
Apixaban Pharmacokinetics in Bariatric Patients (APB)
Completed·JJohns Hopkins University·Phase 4·NCT02406885·33 enrolled
Sugammadex-dosing in Bariatric Patients
Completed·—·Phase 3·NCT01570179·34 enrolled
Pain Control in Bariatric Patients: EXPAREL(R) vs. the On-Q(R) Pain Ball
Completed·Pacira Pharmaceuticals, Inc logoPacira Pharmaceuticals, Inc·Phase 4·NCT02142829·101 enrolled
Evaluation of Dexmedetomidine on Post-operative Narcotic Requirements and Pain Scores in Bariatric Patients
Completed·WWest Virginia University·Phase 4·NCT02604940·46 enrolled
PK of Rivaroxaban in Bariatric Patients - Extension
Completed·IInsel Gruppe AG, University Hospital Bern·Phase 1·NCT02832947·13 enrolled
Regional TAP Block for Bariatric Patients
Completed·MMontefiore Medical Center·Phase 1/2·NCT04051684·23 enrolled
Treatment of GLP-1 for Diabetic Bariatric Patients
Terminated·GGeisinger Clinic·Phase 4·NCT04624672·3 enrolled
The Feasibility of Performing Erector Spinae (ESP) Nerve Block in Bariatric Patients; a Case Series Study
Withdrawn·MMontefiore Medical Center·Phase 2·NCT04477525

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)